{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:35:50Z","timestamp":1791722150375,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["Z20019"],"award-info":[{"award-number":["Z20019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>To explore the effect of liraglutide treatment on serum adropin and its relationship to the liver fat content in newly diagnosed patients with type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated fatty liver disease (MAFLD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Serum adropin level and liver fat content were assessed in patients with T2DM and MAFLD (n\u2009=\u200922), along with healthy controls (n\u2009=\u200922). Afterward, the patients received liraglutide treatment for 12\u00a0weeks. Serum adropin levels were examined by a competitive enzyme-linked immunosorbent assay. Liver fat content was quantified via magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that patients with newly diagnosed T2DM and MAFLD had lower serum adropin levels [2.79\u2009\u00b1\u20090.47 vs. 3.27\u2009\u00b1\u20090.79\u00a0ng\/mL, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05] and higher liver fat content [19.12\u2009\u00b1\u20099.46 vs. 4.67\u2009\u00b1\u20090.61%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001], compared to healthy controls.<\/jats:p>\n                <jats:p>Following 12-week liraglutide treatment, serum adropin levels increased from 2.83(2.44, 3.24) to 3.65(3.20, 3.85)\u00a0ng\/mL (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and liver fat content decreased from 18.04(11.08, 27.65) to 7.74(6.42, 13.49) % (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) in patients with T2DM and MAFLD. Furthermore, increases in serum adropin were strongly associated with decreases in liver fat content (\u03b2\u2009=\u2009\u2212\u20095.933, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), liver enzyme and glucolipid metabolism parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The increase in serum adropin level following liraglutide treatment was strongly correlated with the reduction in liver fat content and glucolipid metabolism. Hence, adropin might be a potential marker for the beneficial effects of liraglutide on treating T2DM and MAFLD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00592-023-02082-3","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T15:58:13Z","timestamp":1682006293000},"page":"971-979","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease"],"prefix":"10.1007","volume":"60","author":[{"given":"Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6957-3814","authenticated-orcid":false,"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"6","key":"2082_CR1","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M et al (2019) Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69(6):2672\u20132682. https:\/\/doi.org\/10.1002\/hep.30251","journal-title":"Hepatology"},{"issue":"2","key":"2082_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","volume":"5","author":"SK Sarin","year":"2020","unstructured":"Sarin SK, Kumar M, Eslam M et al (2020) Liver diseases in the Asia-Pacific region: a Lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol 5(2):167\u2013228. https:\/\/doi.org\/10.1016\/S2468-1253(19)30342-5","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"2082_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158(7):1999\u20132014. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312","journal-title":"Gastroenterology"},{"issue":"8","key":"2082_CR4","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.metabol.2016.01.001","volume":"65","author":"JM Hazlehurst","year":"2016","unstructured":"Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW (2016) Non-alcoholic fatty liver disease and diabetes. Metabolism 65(8):1096\u20131108. https:\/\/doi.org\/10.1016\/j.metabol.2016.01.001","journal-title":"Metabolism"},{"issue":"2","key":"2082_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","volume":"24","author":"KS Tolbol","year":"2018","unstructured":"Tolbol KS, Kristiansen MN, Hansen HH et al (2018) Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol 24(2):179\u2013194. https:\/\/doi.org\/10.3748\/wjg.v24.i2.179","journal-title":"World J Gastroenterol"},{"key":"2082_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.935180","author":"Y Tan","year":"2022","unstructured":"Tan Y, Zhen Q, Ding X et al (2022) Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2022.935180","journal-title":"Front Endocrinol"},{"issue":"4","key":"2082_CR7","doi-asserted-by":"publisher","first-page":"G508","DOI":"10.1152\/ajpgi.00139.2019","volume":"317","author":"T Duparc","year":"2019","unstructured":"Duparc T, Briand F, Trenteseaux C et al (2019) Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 317(4):G508\u2013G517. https:\/\/doi.org\/10.1152\/ajpgi.00139.2019","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"9","key":"2082_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/hepr.12634","volume":"46","author":"W Tong","year":"2016","unstructured":"Tong W, Ju L, Qiu M et al (2016) Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1\/SIRT3-FOXO3a pathway. Hepatol Res 46(9):933\u2013943. https:\/\/doi.org\/10.1111\/hepr.12634","journal-title":"Hepatol Res"},{"key":"2082_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J (2019) The discovery and development of liraglutide and semaglutide. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2019.00155","journal-title":"Front Endocrinol"},{"issue":"2","key":"2082_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1210\/jc.2016-2775","volume":"102","author":"JM Petit","year":"2017","unstructured":"Petit JM, Cercueil JP, Loffroy R et al (2017) Effect of Liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD study. J Clin Endocrinol Metab 102(2):407\u2013415. https:\/\/doi.org\/10.1210\/jc.2016-2775","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2082_CR11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2337\/dc14-2548\/-\/DC1","volume":"38","author":"A Tang","year":"2015","unstructured":"Tang A, Rabasa-Lhoret R, Castel H et al (2015) Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes_ a randomized trial. Diabetes Care 38(7):1339\u20131346. https:\/\/doi.org\/10.2337\/dc14-2548\/-\/DC1","journal-title":"Diabetes Care"},{"issue":"10019","key":"2082_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"key":"2082_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25030549","author":"M Jasaszwili","year":"2020","unstructured":"Jasaszwili M, Billert M, Strowski MZ, Nowak KW, Skrzypski M (2020) Adropin as a fat-burning hormone with multiple functions-review of a decade of research. Molecules. https:\/\/doi.org\/10.3390\/molecules25030549","journal-title":"Molecules"},{"issue":"11","key":"2082_CR14","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.ajem.2016.04.014","volume":"34","author":"B Gulen","year":"2016","unstructured":"Gulen B, Eken C, Kucukdagli OT et al (2016) Adropin levels and target organ damage secondary to high blood pressure in the ED. Am J Emerg Med 34(11):2061\u20132064. https:\/\/doi.org\/10.1016\/j.ajem.2016.04.014","journal-title":"Am J Emerg Med"},{"issue":"1","key":"2082_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/cdt.2018.07.09","volume":"9","author":"J Zheng","year":"2019","unstructured":"Zheng J, Liu M, Chen L et al (2019) Association between serum adropin level and coronary artery disease: a systematic review and meta-analysis. Cardiovasc Diagn Ther 9(1):1\u20137. https:\/\/doi.org\/10.21037\/cdt.2018.07.09","journal-title":"Cardiovasc Diagn Ther"},{"issue":"5","key":"2082_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.rbmo.2021.01.020","volume":"42","author":"Z Ye","year":"2021","unstructured":"Ye Z, Zhang C, Zhao Y (2021) Potential effects of adropin on systemic metabolic and hormonal abnormalities in polycystic ovary syndrome. Reprod Biomed Online 42(5):1007\u20131014. https:\/\/doi.org\/10.1016\/j.rbmo.2021.01.020","journal-title":"Reprod Biomed Online"},{"issue":"7","key":"2082_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1507\/endocrj.EJ18-0060","volume":"65","author":"H Zang","year":"2018","unstructured":"Zang H, Jiang F, Cheng X, Xu H, Hu X (2018) Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index. Endocr J 65(7):685\u2013691. https:\/\/doi.org\/10.1507\/endocrj.EJ18-0060","journal-title":"Endocr J"},{"key":"2082_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.696163","author":"N Li","year":"2021","unstructured":"Li N, Xie G, Zhou B et al (2021) Serum adropin as a potential biomarker for predicting the development of type 2 diabetes mellitus in individuals with metabolic dysfunction-associated fatty liver disease. Front Physiol. https:\/\/doi.org\/10.3389\/fphys.2021.696163","journal-title":"Front Physiol"},{"issue":"6","key":"2082_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.cmet.2008.10.011","volume":"8","author":"KG Kumar","year":"2008","unstructured":"Kumar KG, Trevaskis JL, Lam DD et al (2008) Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 8(6):468\u2013481. https:\/\/doi.org\/10.1016\/j.cmet.2008.10.011","journal-title":"Cell Metab"},{"issue":"Suppl 1","key":"2082_CR20","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2337\/dc13-S011","volume":"36","author":"American Diabetes, A","year":"2013","unstructured":"American Diabetes, A (2013) Standards of medical care in diabetes\u20132013. Diabetes Care 36(Suppl 1):S11-66. https:\/\/doi.org\/10.2337\/dc13-S011","journal-title":"Diabetes Care"},{"key":"2082_CR21","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1000-6699.2011.09.003","author":"CSo, E","year":"2011","unstructured":"CSo, E (2011) Chinese expert consensus for the prevention and treatment of obesity in adults. Chin J Endocrinol Metab. https:\/\/doi.org\/10.3760\/cma.j.issn.1000-6699.2011.09.003","journal-title":"Chin J Endocrinol Metab"},{"issue":"2","key":"2082_CR22","doi-asserted-by":"publisher","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","volume":"288","author":"LS Szczepaniak","year":"2005","unstructured":"Szczepaniak LS, Nurenberg P, Leonard D et al (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288(2):E462\u2013E468. https:\/\/doi.org\/10.1152\/ajpendo.00064.2004","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"2082_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/MJT.0b013e318160b909","volume":"15","author":"V Berm\u00fadez","year":"2008","unstructured":"Berm\u00fadez V, Cano R, Cano C et al (2008) Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes. Am J Ther 15(4):409\u2013416. https:\/\/doi.org\/10.1097\/MJT.0b013e318160b909","journal-title":"Am J Ther"},{"issue":"6","key":"2082_CR24","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.26543","volume":"58","author":"SB Reeder","year":"2013","unstructured":"Reeder SB (2013) Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis. Hepatology 58(6):1877\u20131880. https:\/\/doi.org\/10.1002\/hep.26543","journal-title":"Hepatology"},{"key":"2082_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101167","author":"V Ajmera","year":"2021","unstructured":"Ajmera V, Loomba R (2021) Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab. https:\/\/doi.org\/10.1016\/j.molmet.2021.101167","journal-title":"Mol Metab"},{"issue":"2","key":"2082_CR26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/hep.29797","volume":"68","author":"C Caussy","year":"2018","unstructured":"Caussy C, Reeder SB, Sirlin CB, Loomba R (2018) Noninvasive, Quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology 68(2):763\u2013772. https:\/\/doi.org\/10.1002\/hep.29797","journal-title":"Hepatology"},{"issue":"6","key":"2082_CR27","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/hep.26455","volume":"58","author":"M Noureddin","year":"2013","unstructured":"Noureddin M, Lam J, Peterson MR et al (2013) Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 58(6):1930\u20131940. https:\/\/doi.org\/10.1002\/hep.26455","journal-title":"Hepatology"},{"issue":"7","key":"2082_CR28","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/oby.2012.31","volume":"20","author":"K Ganesh Kumar","year":"2012","unstructured":"Ganesh Kumar K, Zhang J, Gao S et al (2012) Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity 20(7):1394\u20131402. https:\/\/doi.org\/10.1038\/oby.2012.31","journal-title":"Obesity"},{"issue":"25","key":"2082_CR29","doi-asserted-by":"publisher","first-page":"9706","DOI":"10.1074\/jbc.RA119.007528","volume":"294","author":"AA Butler","year":"2019","unstructured":"Butler AA, Zhang J, Price CA et al (2019) Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates. J Biol Chem 294(25):9706\u20139719. https:\/\/doi.org\/10.1074\/jbc.RA119.007528","journal-title":"J Biol Chem"},{"issue":"10","key":"2082_CR30","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1210\/jc.2012-2194","volume":"97","author":"AA Butler","year":"2012","unstructured":"Butler AA, Tam CS, Stanhope KL et al (2012) Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab 97(10):3783\u20133791. https:\/\/doi.org\/10.1210\/jc.2012-2194","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2082_CR31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1515\/jpem-2019-0329","volume":"33","author":"X Yuan","year":"2020","unstructured":"Yuan X, Chen R, Ouyang Q et al (2020) Novel associations of serum adropin and lipopolysaccharide-binding protein versus lipid profiles in childhood obesity. J Pediatr Endocrinol Metab 33(2):265\u2013270. https:\/\/doi.org\/10.1515\/jpem-2019-0329","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"8","key":"2082_CR32","doi-asserted-by":"publisher","first-page":"e3008","DOI":"10.1038\/cddis.2017.362","volume":"8","author":"S Chen","year":"2017","unstructured":"Chen S, Zeng K, Liu QC et al (2017) Adropin deficiency worsens HFD-induced metabolic defects. Cell Death Dis 8(8):e3008. https:\/\/doi.org\/10.1038\/cddis.2017.362","journal-title":"Cell Death Dis"},{"issue":"36","key":"2082_CR33","doi-asserted-by":"publisher","first-page":"13366","DOI":"10.1074\/jbc.RA119.008967","volume":"294","author":"S Gao","year":"2019","unstructured":"Gao S, Ghoshal S, Zhang L et al (2019) The peptide hormone adropin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity. J Biol Chem 294(36):13366\u201313377. https:\/\/doi.org\/10.1074\/jbc.RA119.008967","journal-title":"J Biol Chem"},{"key":"2082_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108536","author":"M Jasaszwili","year":"2020","unstructured":"Jasaszwili M, Wojciechowicz T, Strowski MZ, Nowak KW, Skrzypski M (2020) Adropin stimulates proliferation but suppresses differentiation in rat primary brown preadipocytes. Arch Biochem Biophys. https:\/\/doi.org\/10.1016\/j.abb.2020.108536","journal-title":"Arch Biochem Biophys"},{"issue":"8","key":"2082_CR35","doi-asserted-by":"publisher","first-page":"10056","DOI":"10.1096\/fj.202000115RR","volume":"34","author":"X Chen","year":"2020","unstructured":"Chen X, Chen S, Shen T et al (2020) Adropin regulates hepatic glucose production via PP2A\/AMPK pathway in insulin-resistant hepatocytes. FASEB J 34(8):10056\u201310072. https:\/\/doi.org\/10.1096\/fj.202000115RR","journal-title":"FASEB J"},{"issue":"10","key":"2082_CR36","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.2337\/db14-0388","volume":"63","author":"S Gao","year":"2014","unstructured":"Gao S, McMillan RP, Jacas J et al (2014) Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes 63(10):3242\u20133252. https:\/\/doi.org\/10.2337\/db14-0388","journal-title":"Diabetes"},{"issue":"2","key":"2082_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4149\/bll_2016_020","volume":"117","author":"R Akcilar","year":"2016","unstructured":"Akcilar R, Kocak FE, Simsek H et al (2016) Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy 117(2):100\u2013105. https:\/\/doi.org\/10.4149\/bll_2016_020","journal-title":"Bratisl Lek Listy"},{"issue":"2","key":"2082_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.20471\/acc.2020.59.02.19","volume":"59","author":"T Ticinovic Kurir","year":"2020","unstructured":"Ticinovic Kurir T, Milicevic T, Novak A, Vilovic M, Bozic J (2020) Adropin\u2014potential link in cardiovascular protection for obese male type 2 diabetes mellitus patients treated with liraglutide. Acta Clin Croat 59(2):344\u2013350. https:\/\/doi.org\/10.20471\/acc.2020.59.02.19","journal-title":"Acta Clin Croat"},{"issue":"1","key":"2082_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12933-019-0954-6","volume":"18","author":"YR Wu","year":"2019","unstructured":"Wu YR, Shi XY, Ma CY, Zhang Y, Xu RX, Li JJ (2019) Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1\/2 pathway. Cardiovasc Diabetol 18(1):146. https:\/\/doi.org\/10.1186\/s12933-019-0954-6","journal-title":"Cardiovasc Diabetol"},{"key":"2082_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.602574","author":"Y Fang","year":"2020","unstructured":"Fang Y, Ji L, Zhu C et al (2020) Liraglutide alleviates hepatic steatosis by activating the TFEB-regulated autophagy-lysosomal pathway. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2020.602574","journal-title":"Front Cell Dev Biol"},{"key":"2082_CR41","doi-asserted-by":"publisher","first-page":"111778","DOI":"10.1016\/j.biopha.2021.111778","volume":"140","author":"H Wang","year":"2021","unstructured":"Wang H, Wang L, Li Y et al (2021) The HIF-2alpha\/PPARalpha pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis. Biomed Pharmacother 140:111778. https:\/\/doi.org\/10.1016\/j.biopha.2021.111778","journal-title":"Biomed Pharmacother"},{"key":"2082_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.101068","author":"X Chen","year":"2019","unstructured":"Chen X, Xue H, Fang W et al (2019) Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity. Redox Biol. https:\/\/doi.org\/10.1016\/j.redox.2018.101068","journal-title":"Redox Biol"},{"key":"2082_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2020.08.005","author":"X Chen","year":"2020","unstructured":"Chen X, Sun X, Shen T et al (2020) Lower adropin expression is associated with oxidative stress and severity of nonalcoholic fatty liver disease. Free Radic Biol Med. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.08.005","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"2082_CR44","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1159\/000500106","volume":"28","author":"O Kutlu","year":"2019","unstructured":"Kutlu O, Altun O, Dikker O et al (2019) Serum adropin levels are reduced in adult patients with nonalcoholic fatty liver disease. Med Princ Pract 28(5):463\u2013469. https:\/\/doi.org\/10.1159\/000500106","journal-title":"Med Princ Pract"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-023-02082-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-023-02082-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-023-02082-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:08:05Z","timestamp":1684469285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-023-02082-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["2082"],"URL":"https:\/\/doi.org\/10.1007\/s00592-023-02082-3","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"3 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed written consent was received from all the participants prior to the\u00a0study initiation.\u00a0Approval was obtained from the ethics committee of Beijing Chao-yang Hospital, Capital Medical University. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"All participants voluntarily signed written informed consent statements prior to study initiation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}